CRVO Fundamental Analysis - CERVOMED INC

Fundamental Rating

Overall CRVO gets a fundamental rating of 3 out of 10. We evaluated CRVO against 536 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for CRVO as it has an excellent financial health rating, but there are worries on the profitability. CRVO is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

CRVO had negative earnings in the past year.

In the past year CRVO has reported a negative cash flow from operations.

CRVO had negative earnings in each of the past 5 years.

CRVO had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

CRVO has a Return On Assets (-59.38%) which is comparable to the rest of the industry.

The Return On Equity of CRVO (-67.62%) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-59.38%
ROE	-67.62%
ROIC	N/A

ROA(3y)-42.82%

ROA(5y)-50.07%

ROE(3y)-49.37%

ROE(5y)-56.44%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CRVO so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, CRVO has more shares outstanding

CRVO has more shares outstanding than it did 5 years ago.

CRVO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

CRVO has an Altman-Z score of 6.52. This indicates that CRVO is financially healthy and has little risk of bankruptcy at the moment.

With a decent Altman-Z score value of 6.52, CRVO is doing good in the industry, outperforming 77.61% of the companies in the same industry.

CRVO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	6.52

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 8.20 indicates that CRVO has no problem at all paying its short term obligations.

The Current ratio of CRVO (8.20) is better than 73.88% of its industry peers.

A Quick Ratio of 8.20 indicates that CRVO has no problem at all paying its short term obligations.

CRVO has a Quick ratio of 8.20. This is in the better half of the industry: CRVO outperforms 74.25% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	8.2
Quick Ratio	8.2

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for CRVO have decreased strongly by -48.30% in the last year.

Looking at the last year, CRVO shows a very negative growth in Revenue. The Revenue has decreased by -19.47% in the last year.

EPS 1Y (TTM)-48.3%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-159.26%

Revenue 1Y (TTM)-19.47%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%-46.56%

3.2 Future

Based on estimates for the next years, CRVO will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.34% on average per year.

CRVO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 53.24% yearly.

EPS Next Y-16.4%

EPS Next 2Y-4.34%

EPS Next 3Y1.16%

EPS Next 5Y12.34%

Revenue Next Year-32.68%

Revenue Next 2Y-71.04%

Revenue Next 3Y-25.99%

Revenue Next 5Y53.24%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CRVO. In the last year negative earnings were reported.

Also next year CRVO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-4.34%

EPS Next 3Y1.16%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

CRVO does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CERVOMED INC

NASDAQ:CRVO (10/6/2025, 11:28:49 AM)

8.71

+0.01 (+0.11%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)08-08 2025-08-08/bmo

Earnings (Next)11-10 2025-11-10

Inst Owners23.56%

Inst Owner Change0%

Ins Owners23.55%

Ins Owner Change0.23%

Market Cap80.57M

Analysts80

Price Target19.53 (124.23%)

Short Float %3.04%

Short Ratio0.49

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)3.89%

Min EPS beat(2)-8.93%

Max EPS beat(2)16.71%

EPS beat(4)1

Avg EPS beat(4)-11.86%

Min EPS beat(4)-30.72%

Max EPS beat(4)16.71%

EPS beat(8)3

Avg EPS beat(8)-4.71%

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)1

Avg Revenue beat(2)4.29%

Min Revenue beat(2)-0.58%

Max Revenue beat(2)9.17%

Revenue beat(4)2

Avg Revenue beat(4)-2.02%

Min Revenue beat(4)-37.98%

Max Revenue beat(4)21.32%

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-6.62%

PT rev (3m)20.9%

EPS NQ rev (1m)3.4%

EPS NQ rev (3m)-48.84%

EPS NY rev (1m)-4.07%

EPS NY rev (3m)-13.9%

Revenue NQ rev (1m)-10.42%

Revenue NQ rev (3m)21.43%

Revenue NY rev (1m)-5.44%

Revenue NY rev (3m)15.54%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	10.36
P/FCF	N/A
P/OCF	N/A
P/B	2.41
P/tB	2.41
EV/EBITDA	N/A

EPS(TTM)-2.61

EYN/A

EPS(NY)-2.21

Fwd EYN/A

FCF(TTM)-2.52

FCFYN/A

OCF(TTM)-2.52

OCFYN/A

SpS0.84

BVpS3.62

TBVpS3.62

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-59.38%
ROE	-67.62%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-42.82%

ROA(5y)-50.07%

ROE(3y)-49.37%

ROE(5y)-56.44%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score2

Asset Turnover0.2

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	8.2
Quick Ratio	8.2
Altman-Z	6.52

F-Score2

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-48.3%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-159.26%

EPS Next Y-16.4%

EPS Next 2Y-4.34%

EPS Next 3Y1.16%

EPS Next 5Y12.34%

Revenue 1Y (TTM)-19.47%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%-46.56%

Revenue Next Year-32.68%

Revenue Next 2Y-71.04%

Revenue Next 3Y-25.99%

Revenue Next 5Y53.24%

EBIT growth 1Y-146.79%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-72.16%

EBIT Next 3Y-60.37%

EBIT Next 5Y-24.41%

FCF growth 1Y-68.42%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-68.42%

OCF growth 3YN/A

OCF growth 5YN/A

CERVOMED INC (CRVO) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens